

1 **Morin-Loaded Chitosan-Poloxamer Hydrogel as an Osteoinductive Delivery System for**  
2 **Endodontic Applications**

3 **Short running title:** Morin-loaded hydrogels for endodontics

4 Jesse Augusto Pereira<sup>1</sup>, Victor Martin<sup>2,3\*</sup>, Rita Araújo<sup>2,3</sup>, Liliana Grenho<sup>2,3</sup>, Pedro  
5 Gomes<sup>2,3</sup>, Joana Marto<sup>4</sup>, Maria Helena Fernandes<sup>2,3</sup>, Catarina Santos<sup>5,6</sup>, Cristiane  
6 Duque<sup>1,7\*</sup>.

7 <sup>1</sup>Department of Preventive and Restorative Dentistry, Araçatuba Dental School, São Paulo State  
8 University (UNESP), Araçatuba, São Paulo, Brazil. ([jesseaugusto.p@gmail.com](mailto:jesseaugusto.p@gmail.com), JAP; [cduque@ucp.pt](mailto:cduque@ucp.pt),  
9 CD)

10 <sup>2</sup>BoneLab, **Faculdade de Medicina Dentária, Universidade do** Porto, 4200-393 Porto, Portugal,  
11 [rita.araujosilva@sapo.pt](mailto:rita.araujosilva@sapo.pt), RA; [lgrenho@fmd.up.pt](mailto:lgrenho@fmd.up.pt), LG; [pgomes@fmd.up.pt](mailto:pgomes@fmd.up.pt), PG;  
12 [mhfernandes@fmd.up.pt](mailto:mhfernandes@fmd.up.pt), MHF)

13 <sup>3</sup>LAQV/REQUIMTE, **Faculdade de Medicina Dentária, Universidade do Porto, Rua Dr. Manuel Pereira**  
14 **da Silva, 4200-393 Porto, Portugal.**

15 <sup>4</sup>Research Institute for Medicines (iMed.Ulisboa), Faculty of Pharmacy, Universidade de Lisboa,  
16 1649-003 Lisbon, Portugal. ([jmmarto@ff.ulisboa.pt](mailto:jmmarto@ff.ulisboa.pt), JM)

17 <sup>5</sup>EST Setúbal, CDP2T, Instituto Politécnico de Setúbal, 2910-761 Setúbal, Portugal.  
18 ([catarina.santos@estsetubal.ips.pt](mailto:catarina.santos@estsetubal.ips.pt), CS)

19 <sup>6</sup>CQE Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal.

20 <sup>7</sup>Faculty of Dental Medicine, Center for Interdisciplinary Research in Health (CIIS), Universidade  
21 Católica Portuguesa, Viseu, Portugal.

22 **\*Corresponding authors:**

23 Cristiane Duque

24 Faculty of Dental Medicine, Centre for Interdisciplinary Research in Health (CIIS),  
25 Universidade Católica Portuguesa (Catholic University of Portugal).

26 Rua da Circunvalação, s/n, 3504-505, Viseu, Portugal.

27 Tel: (+351) 232 419 500.

28 E-mail: [cristianeduque@yahoo.com.br](mailto:cristianeduque@yahoo.com.br), [cduque@ucp.pt](mailto:cduque@ucp.pt), [cristiane.duque@unesp.br](mailto:cristiane.duque@unesp.br)

1 Orcid iD: 0000-0002-2575-279X

2 Victor Martin

3 **BoneLab, Faculdade de Medicina Dentária, Universidade do Porto.**

4 Address: Rua Dr. Manuel Pereira da Silva, 4200-393 Porto, Portugal.

5 Tel: (+351) 220 901 100.

6 E-mail: [vmartin@fmd.up.pt](mailto:vmartin@fmd.up.pt)

7 Orcid iD: 0000-0001-6910-1705

## 8 **Funding**

9 This work received financial support from FCT/MCTES (UIDB/50006/2020 DOI  
10 10.54499/UIDB/50006/2020) through national funds.

## 11 **Acknowledgements**

12 The authors acknowledge the support of the i3S Scientific Platform HEMS - Histology  
13 and Electron Microscopy Department.

14 This work received support and help from FCT/MCTES (LA/P/0008/2020 DOI  
15 10.54499/LA/P/0008/2020 and UIDP/50006/2020 DOI 10.54499/UIDP/50006/2020),  
16 through national funds.

## 17 **Data Availability Statement**

18 The data presented in this study are available on request from the corresponding  
19 authors.

## 20 **Conflicts of Interest**

21 The authors declare that they have no conflict of interest or financial interests to  
22 disclose.

23

1 **Abstract**

2 **Objectives:** Considering the search for new biocompatible intracanal medicaments that  
3 can preserve remaining cells and stimulate bone tissue repair in the periapical region,  
4 this study aimed to synthesize and characterize the physicochemical properties of  
5 morin-loaded chitosan-poloxamer hydrogel (MCP) as well as to evaluate its osteogenic  
6 potential.

7 **Methods:** Morin hydrate (M) was loaded into chitosan-poloxamer (CP) hydrogel and the  
8 resulting particles were characterized by infrared spectroscopy (FTIR), UV-vis  
9 spectrophotometer and scanning electron microscopy. Biological assays evaluated the  
10 metabolic activity, cell morphology and alkaline phosphatase (ALP) activity of human  
11 bone marrow stem cells (HBMSC) in three different settings, such as the exposure to  
12 dissolved morin, hydrogel's leachates and assembled particles by indirect contact. Cells  
13 cultured in standard culture conditions were used as control. The effect of CP and MCP  
14 particles on the formation of collagenous and mineralized tissues was also assessed  
15 within the organotypic model of segmented embryonic chick femora. Datasets were  
16 assessed for one-way analysis of variance (ANOVA), followed by Tukey's post hoc test  
17 ( $p < 0.05$ ).

18 **Results:** Morin at 50  $\mu\text{g/mL}$  was cytocompatible and increased ALP activity. CP and MCP  
19 particles showed stability, and morin was entrapped in the hydrogel matrix without  
20 changing its chemical structure. Cultures treated with 30-min CP and MCP hydrogel  
21 leachates presented significantly higher metabolic activity compared to control. By  
22 indirect contact, CP particles increased metabolic activity, but only MCP particles  
23 induced an upregulation of ALP activity in comparison to control. The amount of  
24 collagenous tissue and mineralized area on the fractured embryonic chick femora was  
25 greater in MCP particles compared to CP counterparts.

26 **Significance:** Chitosan-poloxamer platforms are suitable systems to delivery morin,  
27 enhancing cell proliferation and bone mineralization, which upholds its application as  
28 intracanal medication for endodontic purposes.

29

30 **Keywords:** Morin; Chitosan; Poloxamer; Biocompatibility; Osteogenesis; Stem cells;  
31 Drug-delivery.

32

## 1 **Highlights**

- 2 • The MCP hydrogel exhibited osteoblastic cytocompatibility to human bone  
3 marrow stem cells.
- 4 • The MCP hydrogel induced bone formation within the embryonic chick femora  
5 organotypic model.
- 6 • The MCP hydrogel holds potential as a medication for endodontic purposes.

7

## 8 **1. Introduction**

9 Apical periodontitis is a chronic inflammatory process that develops around the  
10 dental apex, commonly in permanent teeth, mainly triggered by bacterial invasion from  
11 the pulp affected by caries or trauma [1]. In addition to the direct harmful effect of  
12 bacterial products, the active immune inflammatory response in the region generates  
13 an intracellular signaling cascade, involving the production of inflammatory cytokines  
14 that are related to the migration of inflammatory cells and osteoclastogenesis [2,3]. This  
15 process culminates in the disruption of bone homeostasis and the upregulation of  
16 resorption factors with consequent bone loss and the formation of periapical lesions [4].

17 The treatment of teeth with apical periodontitis involves the chemical-  
18 mechanical preparation of the root canals with bactericidal irrigating solutions and  
19 subsequent application of intracanal medication. In immature permanent teeth with  
20 apical periodontitis, clinical treatment is more challenging, since these teeth have short  
21 roots with thin, parallel dentin walls that make irrigation procedures difficult, and the  
22 presence of an open and still developing apex. Traditional endodontic treatment  
23 (apexification) uses irrigating chemical substances such as sodium hypochlorite or  
24 chlorhexidine. **However, when used at the recommended high concentrations, these**  
25 **substances can compromise the viability of the remaining cells in the pulp tissue or**  
26 **adjacent areas, potentially disrupting** root formation [5, 6]. Traditionally, periodic  
27 exchanges of calcium hydroxide with intracanal medication are also recommended due  
28 to its physicochemical and antimicrobial properties. However, its alkalinity also hampers  
29 the viability of residual cells and does not promote continued root development [7].  
30 Therefore, **the development of alternative biocompatible solutions and intracanal**

1 medicaments is highly relevant, as they can preserve remaining cells to guide root  
2 formation and stimulate tissue repair in the periapical region [8,9].

3 Plant-derived bioactive compounds, such as flavonoids, have received attention  
4 in the literature due to their wide range of therapeutic applications. Studies have  
5 highlighted several pharmacological properties of flavonoids - polyphenols present in  
6 fruits, seeds, and vegetables - such as antimicrobial, antioxidant, anti-inflammatory,  
7 osteogenic and antiosteoclastogenic actions, among others [10-12]. Flavonoids include  
8 flavones, flavonols, flavanones, flavanonol, flavanols, anthocyanidins and chalcones  
9 [12]. Morin is a flavonol (3,5,7,2',4'-pentahydroxyflavone) found in several plants,  
10 including *Morus alba L* (white mulberry), *Prunus dulcis* (almond), *Castanea sativa* (sweet  
11 chestnut), *Psidium guajava* (guava), among others [13, 14]. Morin has demonstrated  
12 radical scavenging, antioxidant, anti-inflammatory, anti-cancerous, antimicrobial,  
13 antidiabetic, anti-arthritis, cardioprotective, neuroprotective, nephroprotective, and  
14 hepatoprotective effects [14, 15]. Furthermore, its applicability as a medicine also  
15 becomes viable due to its low cytotoxicity [16,17].

16 Morin was also employed as a medication for dentistry applications. Studies have  
17 demonstrated the inhibitory effect of morin on planktonic bacteria commonly isolated  
18 from oral infections [10,18-20] and on dental biofilm formation [21-24]. Moreover, the  
19 ability of morin in repairing bone defects was demonstrated in mice by inducing  
20 differentiation of mesenchymal cells and by activating classical signaling pathways,  
21 which culminated in the upregulation of genes related to bone mineralization, as well as  
22 in the decrease of bone resorption markers [11, 25].

23 To take advantage of the full potential of morin, therapeutic applications must  
24 focus on local delivery approaches, relying on biocompatible and biodegradable delivery  
25 carriers, such as hydrogels. These systems can improve the solubility and stability of  
26 phytochemicals, in addition to protecting them from early degradation by body fluids  
27 [25]. One of the most studied natural polymers is chitosan, a polysaccharide of animal  
28 origin obtained from the chitin of the exoskeleton of crustaceans [25,26]. Chitosan has  
29 the ability to form a hydrogel under suitable conditions, however it has low mechanical  
30 strength and poor absorption in water solutions [26]. Poloxamer 407 is another polymer  
31 commonly used in various drug delivery systems, including in combination with  
32 chitosan. It offers innumerable advantages, such as thermoreversibility, low toxicity,

1 biocompatibility, ability to enhance biomolecules solubilization and **the ability to**  
2 **prolong the release** profile for many applications [27,28]. Thus, the present study aimed  
3 to develop and characterize an innovative **hydrogel loaded with morin, with osteogenic**  
4 **effects**, devised to be an alternative treatment for apical periodontitis. The carrier  
5 consists of a mixture of a natural polymer, chitosan, and a synthetic polymer, poloxamer  
6 407, to provide low toxicity, biocompatibility, and an optimal profile for the controlled  
7 release of morin.

## 9 **2. Methods**

### 10 *2.1. Morin and controls*

11 Unless otherwise specified, compounds and reagents were purchased from  
12 Sigma-Aldrich® (St. Louis, MO, USA) and cell culture media from ThermoFisher  
13 Scientific® (Waltham, MA, USA). Morin hydrate powder (#M4008) was dissolved in  
14 dimethyl sulfoxide (DMSO) cell culture-grade to obtain a stock solution of 25.2 mg/mL.  
15 Then, the stock solution **was sterilized** using a 0.2 µm syringe filter. Working solutions at  
16 selected concentrations were obtained by diluting the stock solution with α-Minimal  
17 Essential Medium (α-MEM) culture medium for cytological assays. The percentage of  
18 DMSO in working solutions was kept < 0.05% v/v. Control cultures receiving analogous  
19 volume of DMSO without **added** morin were considered as control groups (set as 100%  
20 growth/metabolism). **The assays were performed in three independent days.**

### 22 *2.2. Synthesis of Morin-loaded chitosan-poloxamer (MCP) hydrogels and assembly of* 23 *MCP particles*

24 Morin-loaded **chitosan-poloxamer hydrogels** were synthesized via an ionotropic  
25 gelation technique [29]. First, chitosan from shrimp exoskeleton (molecular weight 10-  
26 50kd, viscosity 20-300cps, deacetylation degree 80-95%) (1% wt./vol) was dissolved in a  
27 solution of acetic acid (1% wt./vol) **using a mechanical stirrer** (600 rpm) for about 3 h.  
28 Parallely, poloxamer 407 (HP-407, Kolliphor 407: contains nominally 95 to 105 ethylene  
29 oxide units and 54 to 60 propylene oxide units, with a rough concentration of  
30 oxyethylene of 71.5 to 74.9 %) (10% wt./vol) was mixed with morin (2 mg/mL) under  
31 magnetic stirring (600 rpm) at room temperature. Afterwards, chitosan solution was

1 combined with the morin-ploxamer 407 solution in a 1:1 (vol/vol) ratio and stirred for  
2 5 min to yield a morin-chitosan-ploxamer (MCP) hydrogel.

3 The MCP hydrogel (prepared as described above) was formulated as particles for  
4 transportation and physicochemical analysis by dripping it into a 1 M NaOH solution.  
5 The resulting MCP particles were subjected to magnetic stirring for 10 minutes at 600  
6 rpm in the NaOH solution. The supernatant was then discarded, and the MCP particles  
7 were washed with Milli-Q water. The washing procedure was repeated three times.  
8 Finally, particles were dried in a desiccator overnight. In the present work, the gel  
9 particles were prepared with aliquots of 50  $\mu$ L of the respective solution. The same  
10 procedure was applied to produce chitosan-ploxamer (CP) hydrogel, as well as the  
11 designated CP particles, without morin.

### 12 13 2.3. Physicochemical characterization of MCP hydrogels and particles

14 Fourier transformed infrared spectroscopy (FTIR) spectra of morin, CP and MCP  
15 hydrogels were recorded on a Nicolet (Thermo-Electron Corp, ThermoFisher)  
16 spectrometer using with an attenuated total reflectance (ATR) apparatus. The spectra  
17 were collected in the scanning range 4000  $\text{cm}^{-1}$  to 600  $\text{cm}^{-1}$ , with a resolution of 4  $\text{cm}^{-1}$   
18 and 128 scans. The surface of CP and MCP particles was observed using a scanning  
19 electron microscope (SEM). The EDS analysis of morin was carried out using the same  
20 equipment. The CP and MCP particles were coated with a thin conductive chromium or  
21 gold/palladium film (Model E5100 Sputter Coater, Polaron, Quorum Technologies) and  
22 scanned under a Phenom ProX G6 Desktop electron microscope operating at a voltage  
23 20 kV. The surface charge of CP and MCP particles was evaluated through zeta potential  
24 measurements using a Malvern ZetaSizer Nano ZS instrument. Measurements were  
25 carried out at 25  $^{\circ}$ C, in triplicate. Moreover, the morin content encapsulated within the  
26 MCP particles was assessed using a UV-vis spectrophotometer (GENESYS™ 50 UV-  
27 Visible, ThermoFisher). In this assay, MCP particles were incubated in 1 mL of PBS and  
28 centrifuged at 3,000 rpm, forcing the complete release of the loaded morin. The  
29 absorbance of the supernatant was measured at 410 nm (the peak absorption of morin  
30 in PBS). Subsequently, the encapsulation efficiency was calculated using the formula  
31 provided below:

$$32 \quad ((W-w_s)/W) \times 100$$

1 where W is the amount of the morin initially added to **chitosan-poloxamer (MCP)** and  
2  $w_s$  is the amount of the morin present in the **supernatant of the MCP particles**.

#### 3 4 **2.4. Release profile of morin from the MCP particles**

5 To quantify the morin release, MCP and CP particles were prepared as described  
6 in the section 2.2. Each unit of the particles was incubated with 1 mL of PBS at 37 °C.  
7 Aliquots of 100 µL of the supernatant were collected at predetermined intervals (30 min,  
8 1 h, 3 h, 6 h, 24 h), and the withdrawn volume was replaced with fresh PBS. Morin  
9 content in the collected leachates was determined by measuring the supernatant's  
10 absorbance at 410 nm using a microplate reader (Synergy HT, BioTek). A calibration  
11 curve ( $R^2=0.999$ ) was prepared upon a concentration range of 0.97–250 µg/mL of morin  
12 for the conversion of the absorbance values into morin concentrations. Results are  
13 presented as the cumulative release (%) of morin. Assays were performed in triplicate.

#### 14 15 **2.5. In vitro assessment using HBMSCs cultures**

16 Human bone marrow stem cells (HBMSCs, Lonza, PT-2501) from the 5<sup>th</sup> passage  
17 were used in the **cellular experiments**. HBMSCs were expanded in  $\alpha$ -MEM  
18 supplemented with 10% (vol/vol) fetal bovine serum (FBS), penicillin (100 IU/mL),  
19 streptomycin, (100 µg/mL), and amphotericin B (2.5 µg/mL). Cells were kept at 37 °C  
20 with 5% CO<sub>2</sub> in air. **Once the cultures** reached 70% confluence, cells were trypsinized and  
21 sub-cultured **at a density of** 10,000 cells/cm<sup>2</sup>, and the culture medium was further  
22 supplemented with osteogenic inducers (10 mM  $\beta$ -glycerophosphate, 50 µg/mL of  
23 ascorbic acid and 10 nM dexamethasone). **Three** distinct experimental approaches were  
24 set: assays comprising **exposure to** 1) morin at 10, 50 and 100 µg/mL<sup>1</sup> dissolved in culture  
25 media; 2) **hydrogel's leachates, collected after incubating 50 µL of each CP and MCP**  
26 **hydrogel in 1 mL of culture medium at 37 °C for 30, 60, 180, and 360 minutes**; and 3)  
27 assembled particles (CP and MCP) evaluated through indirect contact, in which cells  
28 were grown at the bottom of 24-well plates attached with permeable inserts (Transwell  
29 6.5 mm insert, 0.4 µm permeable membrane, Costar), where the particles were placed  
30 [30].

### 1 *2.5.1. Metabolic activity*

2 The metabolic activity of HBMSCs cultures was assessed using the resazurin  
3 assay. At selected timepoints, culture media were replaced by fresh media containing  
4 10% v/v of 100 µg/mL resazurin solution (Sigma-Aldrich). Cells were incubated for 3 h at  
5 37 °C. Then, media were collected, and their fluorescence was measured at 530/590 nm  
6 (excitation/emission) using a microplate reader (Synergy HT). **Results are expressed as a**  
7 **% of the control. Experiments were performed in quintuplicate.**

### 9 *2.5.2. Cell morphology*

10 HBMSCs' morphology was evaluated through fluorescence microscopy, using a  
11 Celena S digital imaging system (Logos Biosystems, Villeneuve d'Ascq, France). At  
12 determined timepoints, cells were washed and fixed with 3.7% paraformaldehyde. Fixed  
13 cells were permeabilized with 0.1% Triton-X and incubated with bovine serum albumin  
14 to avoid non-specific interactions. Subsequently, cellular F-actin' cytoskeleton was  
15 stained with phalloidin-conjugated Alexa Fluor 488 (Molecular Probes, Eugene, Oregon,  
16 USA) and their nuclei were counter-stained with Hoechst 33342 (Enzo Life Sciences,  
17 Farmingdale, NY), prior to microscope observation. **Assays were performed in triplicate.**

### 19 *2.5.3. Alkaline Phosphatase activity*

20 Alkaline Phosphatase (ALP) was quantified in cell lysates that were obtained by  
21 adding Triton-X 0.1% to the cultures. Briefly, an alkaline p-nitrophenyl phosphate  
22 solution (**ALP substrate**) was added to cell lysates prior incubation at 37 °C, for 1 h. Then,  
23 the reaction was stopped using NaOH 3 M, **and the reaction product (p-nitrophenol)** was  
24 measured at 405 nm using a microplate reader (Synergy HT). Moreover, the levels of  
25 total protein (TP) of cell lysates were quantified relying on the Lowry's method, using a  
26 DC protein kit (Bio-Rad, **Hercules, California, USA**), read at 750 nm using the same  
27 microplate reader. For each sample, ALP levels were normalized to the corresponding  
28 TP levels. **Results are expressed as a % of the control. Experiments were performed in**  
29 **quintuplicate.**

## 2.6. *Ex vivo* assessment using embryonic chick femora model

The influence of morin on the formation of collagenous and mineralized tissues was assessed within the embryonic chick femora organotypic model. Fertilized chick eggs (*Gallus domesticus*) were purchased from a certified seller. Eggs were placed in an automatic egg incubator (Octagon Advance, Brinsea, Weston-super-Mare, UK) until the 11<sup>th</sup> day of development. Afterwards, femora from euthanized chick embryos were dissected and placed into Netwell® inserts (Costar 3480, 440-µm pore diameter) in 6-well plates. Organotypic cultures were incubated at air/liquid interface at 37°C and 5% CO<sub>2</sub> in air, nourished with α-MEM culture medium supplemented with ascorbic acid (50 µg/mL), penicillin (100 U/mL), streptomycin (100 µg/mL), and amphotericin-B (2.5 µg/mL). After 24 h, femora were cut cross-sectionally in the middle of the diaphysis, and the halves were split. Assembled CP and MCP particles were placed surrounding the diaphyseal area of both halves in experimental groups, while control samples were grown in the absence of any treatment. Culture medium was changed daily, during the subsequent 11 days. Then, femora were fixed in buffered formalin and enclosed in paraffin blocks, prior their sectioning (5 µm-thick). Sections were marked with Alcian Blue with Sirius Red (AB/SR) or Von Kossa (VK) dyes. AB/SR coloration reveals glycosaminoglycans (blue) and collagenous matrix (red), while VK highlights mineralized tissues, producing dark areas. Images were taken using a Zeiss Axiocam 5 Color Camera attached to a Zeiss Axiolab 5 microscope. After photodocumentation, the following histomorphometric indexes were determined using open-source software ImageJ (version 1.54h): Collagen deposition area and mineralized area. Otsu algorithm was used for image segmentation prior measurements [31]. Results are expressed as a % of the control. Assays were performed in triplicate. It is noteworthy that the use of avian embryos within the first two-thirds of development for research purposes is not covered by European (Directive 2010/63/EU) or National (Decreto-Lei n.º 113/2013) legislations, precluding the requirement of regulatory approval for the experimental procedures.

## 2.7. Statistical analysis

Statistical analysis was accomplished using the SPSS Statistics software (version 28, IBM). The normal distribution (Shapiro-Wilk's test) and homogeneity of variances (Levene's test) were checked. Datasets were assessed for one-way analysis of variance

1 (ANOVA), followed by Tukey's post hoc test. The significance level was set at  $p < 0.05$ .  
2 Data were displayed as **mean  $\pm$  standard deviation (SD)**.

3


### 4 **3. Results**

#### 5 *3.1. Physicochemical characterization and release profile of MCP hydrogels*

6 **CP and MCP hydrogels were synthesized via an ionotropic gelation technique, and**  
7 **the prepared gel particles were characterized for morphology, surface charge, chemical**  
8 **composition and morin loading efficiency and release profile.**


9 The interaction between morin and the chitosan-poloxamer hydrogels was  
10 investigated by an ATR-FTIR analysis (supplementary image). In brief, since both  
11 chitosan and poloxamer possess chemical groups vibrating at similar wavenumbers ( $\text{cm}^{-1}$ )  
12 <sup>1</sup> of morin [32-38], it was challenging to conclusively confirm its presence within the  
13 MCP hydrogel. However, it was evident that morin does not chemically bond with either  
14 chitosan or poloxamer.

15 **Optical microscopy was applied to observe the morphology and size of CP and**  
16 **MCP particles, while scanning electron microscopy was used for visualizing the surface**  
17 **of morin, CP and MCP particles (Figure 1). Morin (M) presents a rod like shape (Figure**  
18 **1b) with no other chemical element apart from carbon and oxygen (Figure 1c). The**  
19 **palladium and gold detected in the EDS results (Figure 1c) are from the coating applied**  
20 **to make the sample more conductive. Macroscopically, CP particles (Figure 1d) display**  
21 **a spherical type of morphology, with a subtle and translucent white hue, in addition to**  
22 **an almost uniform and smooth surface (Figure 1e-f). Regarding the MCP particles, a**  
23 **similar morphology can be noted, as well as a yellowish tone and a higher surface**  
24 **roughness (Figure 1g-i). Analysis of zeta potential measurements indicates that both**  
25 **particle types carry a negative surface charge. The average zeta potential value for CP is**  
26 **determined to be  $-25.5 \pm 1.4$  mV, while for MCP it is  $-27.2 \pm 1.1$  mV, suggesting an**  
27 **overall high stability of the particles [39].**



**Figure 1.** Characterization of morin (M) and the synthesized particles. Morin' chemical structure (a), morphology (b) and chemical composition (c), assessed through SEM and EDS. Light (d, g) and SEM representative images from the surface of CP (e, f), and MCP (h, i) hydrogel particles. (n=3).


UV-vis spectroscopy evaluation revealed an encapsulation efficiency of morin within each MCP particle of approximately 70%, as the total morin quantified in the supernatant per unit reached approx. 35  $\mu\text{g/mL}$  (data not shown). To quantify the amount of morin leached per time from MCP particles, samples were placed into PBS for 24 h and the supernatant was collected at selected timepoints (30 min to 24 h). Throughout the assessed period, morin release peaked at 30 min reaching approximately 50%, and progressively dropped until 6 h (Figure 2). Thus, the percentage of morin release was about 90% after 6 h.



1  
2 **Figure 2.** Cumulative released morin from the loaded chitosan-poloxamer (MCP) particles  
3 assessed by colorimetric evaluation. (n=3, SD 1.7 – 5.6%).

4  
5 **3.2. Cytotoxicity and pro-osteogenic potential of morin**

6 The cytocompatibility of morin dissolved in DMSO was assessed using *in vitro*  
7 HBMSCs cultures. In comparison to control (0 µg/mL of morin), cells incubated for 7 days  
8 with morin at 10 and 50 µg/mL presented analogous metabolic activity, evidencing its  
9 cytocompatibility (Figure 3a). At a concentration as high as 100 µg/mL, metabolic  
10 activity was found to be significantly reduced (i.e., approx. 30%) in relation to control  
11 and lower concentrations of morin. To evaluate whether morin induced osteogenic  
12 effects in early cultures of HBMSCs, ALP activity was quantitatively assessed. As  
13 displayed in Figure 3b, low concentrations of the compound (i.e. 10 µg/mL) seemed to  
14 not induce significant changes in the ALP levels. However, at 50 µg/mL, a significant  
15 increase was noted, while a clear reduction was attained with 100 µg/mL. Cell  
16 morphology was observed using fluorescence microscopy (Figure 3, lower panel).  
17 Control cultures were uniform and predominantly forming cellular clusters. HBMSCs  
18 exhibited an elongated cytoskeleton, with abundant parallel actin stress fibers across  
19 their cytoplasm and spike-shaped membrane protrusions were widespread. Rounded  
20 and defined nuclei were evident. Cells from all experimental groups were found to be  
21 alike regarding their morphology and organization. Nonetheless, cells incubated with  
22 100 µg/mL morin seemed to be less confluent in comparison to other groups, aligning  
23 with the observed reduced metabolic activity.




1  
2  
3  
4  
5  
6  
7  
8  
9

**Figure 3.** In vitro biological characterization of morin. Normalized metabolic activity (a), quantitative ALP activity (b) and representative fluorescent images of cell morphology (lower panel) of HBMSCs cultivated in osteogenic medium and morin for 7 days. **Control (Morin at 0 µg/mL)** is set at 100%. Stained F-actin is displayed in green, while nuclei were counter-stained in blue. Scale bar corresponds to 100 µm. \* Statistically different from control. # Statistically different from other experimental groups.  $p < 0.05$ . Metabolic and ALP activities,  $n=5$ . Cell morphology,  $n=3$ . SD 3.2 to 6.6%.



### 10 3.3. Cytotoxicity and pro-osteogenic potential of CP and MCP hydrogels

11 Firstly, the metabolic activity of HBMSCs was evaluated when cells were  
12 incubated with hydrogel leachates. As shown in **Figure 4**, all isolated leachates from CP  
13 hydrogel and MCP hydrogel increased the cellular metabolic activity at both timepoints  
14 (24 h and 7 days). It is worth noting that the 30-min leachates induced the highest  
15 increase at both timepoints, and exposure to MCP hydrogel leachates resulted in  
16 significantly higher values in comparison to control, at 24 h (**Figure 4a**), tendency that  
17 was kept at 7 days (**Figure 4b**).



**Figure 4.** Normalized metabolic activity of HBMSCs cultivated with leachates of chitosan-poloxamer hydrogels (CP and MCP) for 24 h (a) and 7 days (b). X axis values represent the timepoints of leachates' collection. Control (absence of leachates of the referred timepoint) is set as 100%. \* Statistically different from control.  $p < 0.05$ ,  $n=5$ . SD 5.4 to 19.7%.

HBMSCs were also cultured for 7 days in indirect contact with assembled particles (CP or MCP) using Transwell-mounted plates. As displayed is **Figure 5a**, CP particles promoted an increased metabolic activity compared to the control, while MCP particles values remained similar to the control. Oppositely, only the formulation containing morin induced an upregulation of ALP activity in comparison to control cultures (**Figure 5b**). This is in line with the results observed from morin-only incubation at 50  $\mu\text{g/mL}$  (**Figure 4**). Likewise, HBMSCs' morphology was found to be unaffected in the presence of gels (**Figure 5**, lower panel).




**Figure 5.** Normalized metabolic and ALP activity (upper panel) and representative fluorescent images (lower panel) of HBMSCs cultivated indirectly with chitosan-poloxamer gels (blank and containing morin) in osteogenic medium for 7 days. Control (C, absence of particles) is set as

1 100%. F-actin is stained in green, and nuclei were counter-stained in blue. Scale bar is set as 100  
2  $\mu\text{m}$ . \* Statistically different from control.  $p < 0.05$ . Metabolic and ALP activities,  $n = 5$ , Cell  
3 morphology,  $n = 3$ . SD 9.5 – 13.9%.

4

#### 5 *3.4. Pro-osteogenic effect of CP and MCP particles in organotypic bone model*

6 The pro-osteogenic activity of the particles was further evaluated through their  
7 direct contact to organotypic cultures of segmented chicken femora for 11 days. As  
8 noted in **figure 6a**, the fractured area from control femora presented an irregular  
9 morphology, composed primarily of cartilage (in blue), with diminished amounts of  
10 collagen (in red) on the edge of the fracture. Unexpectedly, both particles were stained  
11 in red. Moreover, the amount of collagenous tissue on the edge of the fractured femora  
12 was greater, particularly in the MCP particle group, confirmed by the quantitative  
13 analysis (**Figure 6c**). Differences among groups seemed to be less evident with VK's  
14 staining (**Figure 6b**). Nonetheless, experimental groups presented trabeculae through  
15 the outer layer of femora, indicating a further developed mineralization, which resulted  
16 in significantly increased mineralized area (**Figure 6c**).



**Figure 6.** Representative images of histological sections of the organotypic bone model. Femora were fractured and involved with chitosan-poloxamer gels (blank and containing morin). Samples were incubated for 11 days. (a) Femora sections were stained with Alcian Blue with Sirius Red AB/SR (particles were stained in red), and (b) Von Kossa. Scale bar was set as 1 mm. (c) Quantitative analysis of collagen deposition and mineralized area. Control (absence of particles) is set as 100%. \*Statistically different from control. # Statistically different from other experimental samples. \*  $p < 0.05$ ,  $n=3$ . SD 8.8 – 12.4%.

#### 4. Discussion

In this study, chitosan-poloxamer hydrogels loaded with morin hydrate (MCP) were firstly synthesized and physiochemically studied in hydrogels. Based on the ATR-FTIR results of morin and the CP and MCP hydrogels, it was evident that morin does not chemically bond with either chitosan or poloxamer, indicating that morin is entrapped within the matrix without altering its chemical structure, as observed in other studies [40-42]. Analysis of zeta potential measurements indicates that both particle types (CP and MCP) carry a negative surface charge, suggesting an overall good dispersion stability

1 of the particles. Zeta potential plays a crucial role in evaluating particle dispersion  
2 stability and exerts a significant influence on biological response [39]. The magnitude of  
3 the zeta potential reflects the repulsive forces within the particle dispersion. It has been  
4 observed that hydrogels with a zeta potential value exceeding -25 mV tend to exhibit  
5 stability due to electric repulsion among the particles [39].

6 In the current study, morin alone or loaded in chitosan-poloxamer particles  
7 increased the expression of the osteogenic markers: ALP activity, collagen deposition  
8 and bone mineralization. Additionally, the cytocompatibility of morin was observed at  
9 concentrations of 10 and 50 µg/mL in HBMSCs exposed for 7 days. However, at 100  
10 µg/mL, morin significantly reduced cell metabolic activity. In addition, morin at 50 µg/mL  
11 promoted a significant increase on ALP activity by HBMSCs. These findings are in line  
12 with previous studies, where morin was found to be cytocompatible at a concentration  
13 range of 25–75 µg/mL using mesenchymal stem cells [11] and its half-maximal inhibitory  
14 concentration (IC<sub>50</sub>) was approx. 250 µM (80 µg mL<sup>-1</sup>) in human leukocytes [16].  
15 Furthermore, *in vivo* investigations demonstrated that morin is well tolerated by  
16 humans, with no adverse effects being observed at doses up to 300 mg/Kg [17].

17 To evaluate the developed formulations with and without morin, two different  
18 *in vitro* approaches were performed using HBMSCs. Firstly, the leachates obtained from  
19 CP and MCP hydrogels at predetermined timepoints were added to culture media and,  
20 secondly, by an indirect incubation, where permeable inserts carrying CP and MCP  
21 particles allowed a continuous flux of its leachates to the cultures for 7 days.

22 Leachates collected after 30 min (the maximum morin release, as observed in  
23 Figure 2) induced the highest metabolism increase at 24 h and 7 days timepoints for  
24 both hydrogels. On the contrary, when cultured indirectly, CP particles promoted an  
25 increased metabolic activity in relation to control, while MCP particles induced a  
26 significant increase on ALP activity.

27 Vimalraj et al. [43] assessed morin and morin-zinc complexes using different cell  
28 lines (e.g., human osteoblast-like cells (MG-63), mouse mesenchymal stem cells and rat  
29 myoblast cells) and no cytotoxic effects were noted at concentrations up to 60 µM (20  
30 µg/mL). Interestingly, when cultured with morin at this concentration, MG-63 cells  
31 exhibited a significant increase in ALP activity, calcium deposition, gene expression of  
32 osteogenic-related genes (i.e., RUNX2 and COL1A1) and secretion of osteocalcin (OCN)

1 and osteonectin, evidencing the osteogenic effects of morin. Similarly, mesenchymal  
2 stem cells also showed a remarkable increase on ALP, calcium deposition and the  
3 expression of the osteogenic genes Runx2, ALP, OCN and ColA1 when cultured with  
4 morin (at 0.6 µg/mL) and osteogenic medium for 14 days [11].

5 Few studies have examined the osteogenic potential of chitosan-based drug  
6 delivery systems containing morin [28, 42]. Ultraviolet-cross-linkable-chitosan carbon  
7 dots-morin hydrogel also increased collagen expression and proliferation in  
8 chondrocytes, and cartilage and subchondral bone tissue repair in rats [28]. The  
9 effectiveness of morin encapsulated chitosan nanoparticles (MCNPs) were evaluated  
10 against arsenic induced liver damage in mice. MCNPs suppressed the arsenic induced  
11 pro- and anti-apoptotic parameters and attenuated the level of inflammatory mediators  
12 [42]. The thermosensitivity of poloxamer 407 is also a key advantage for oral application  
13 such as apical periodontitis, since its viscosity tends to increase in temperatures above  
14 30 °C, maintaining the formulation stability for longer periods [27,37]. In addition,  
15 studies indicate that poloxamer 407 is also bioactive, fostering wound healing through  
16 neo-angiogenesis, cell migration and collagen deposition and maturation [44,45].

17 Lastly, the osteogenic activity of CP and MCP particles was evaluated on  
18 organotypic cultures of chicken femora. This *ex vivo* model preserves the three-  
19 dimensional matrix of the bone tissue, fundamental to cellular differentiation and tissue  
20 development [46]. Moreover, the developing femur possesses undifferentiated  
21 progenitor cells, being highly responsive to external stimuli and may mimic the open  
22 apex of teeth, holding translational relevance to the apical development [47].

23 As observed in **Figure 6**, experimental groups (**CP and MCP particles**) presented  
24 enhanced collagen deposition in relation to control, and specimens treated with MCP  
25 particles showed the highest collagen deposition and mineralized areas on the fractured  
26 femora. Comparatively, it has been documented [11] that the administration of morin  
27 improved bone regeneration in animal models with calvaria critical defects in a dose-  
28 dependent manner (50, 100 and 150 mg/kg/day). In another study, intraperitoneal  
29 morin administration in rats with osteoporosis (induced by dexamethasone) increased  
30 the number of trabecular bones through the regulation of MAPK signaling pathway [25].  
31 Ultraviolet-cross-linkable-chitosan carbon dots-morin hydrogel also increased collagen

1 expression and proliferation in chondrocytes, and cartilage and subchondral bone tissue  
2 repair in rats [28].

3

#### 4 **5. Conclusions**

5 This study reports for the first time the suitability of chitosan-poloxamer carriers  
6 to be loaded with morin and, further, to be an effective vehicle to delivery polyphenols  
7 such as this molecule, presenting a release profile compatible with optimal cellular  
8 function.

9 The chitosan-poloxamer hydrogels were comprehensively evaluated *in vitro*,  
10 demonstrating high cytocompatibility. Moreover, the osteogenic potential of morin is  
11 demonstrated, as cells exhibit enhanced proliferation and differentiation, evidenced by  
12 heightened metabolic and ALP activity, respectively. This is further supported by the  
13 results in the *ex vivo* model analysis, where the collagen deposition and mineralization  
14 are elicited by the developed particles.

15 Taken together, the attained data converge to demonstrate the potential of  
16 morin loaded chitosan-poloxamer carriers to be used as therapeutic alternative for  
17 apical inflammatory condition.

18

#### 19 **Funding**

20 This work received financial support from FCT/MCTES (UIDB/50006/2020 DOI  
21 10.54499/UIDB/50006/2020) through national funds.

#### 22 **Acknowledgements**

23 The authors acknowledge the support of the i3S Scientific Platform HEMS - Histology  
24 and Electron Microscopy Department.

25 This work received support and help from FCT/MCTES (LA/P/0008/2020 DOI  
26 10.54499/LA/P/0008/2020 and UIDP/50006/2020 DOI 10.54499/UIDP/50006/2020),  
27 through national funds.

#### 28 **Data Availability Statement:**

1 The data presented in this study are available on request from the corresponding  
2 authors.

### 3 **Conflicts of Interest:**

4 The authors declare that they have no conflict of interest or financial interests to  
5 disclose.

6

### 7 **References**

- 8 [1] Siqueira JF, Magalhães KM, Rôças IN. Bacterial reduction in infected root canals  
9 treated with 2.5% NaOCl as an irrigant and calcium hydroxide/camphorated  
10 paramonochlorophenol paste as an intracanal dressing. *J Endod* 2007;33:667–  
11 672. <http://doi.org/10.1016/j.joen.2007.01.004>
- 12 [2] Bahuguna R, Jain A, Khan SA, Arvind MS. Role of odanacatib in reducing bone loss  
13 due to endodontic disease: An overview. *J Int Soc Prev Comm* 2016;Dent 6: S175-  
14 S181. <http://doi.org/10.4103/2231-0762.197183>
- 15 [3] Krum SA, Chang J, Miranda-Carboni G, Wang CY. Novel functions for NFκB:  
16 inhibition of bone formation. *Nat Rev Rheumatol* 2010; 6:607-611.  
17 <http://doi.org/10.1038/nrrheum.2010.133>
- 18 [4] Siqueira Jr JF, Roças IN. Present status and future directions: microbiology of  
19 endodontic infections. *Int Endod J* 2022;55:512–530.  
20 <http://doi.org/10.1111/iej.13677>
- 21 [5] Ring KC, Murray PE, Namerow KN, Kuttler S, Garcia-Godoy F. The comparison of  
22 the effect of endodontic irrigation on cell adherence to root canal dentin. *J Endod*  
23 2008;34:1474–1479. <http://doi.org/10.1016/j.joen.2008.09.001>
- 24 [6] Ruksakiet K, Farkas LHN, Hegyi P, Sadaeng W, Czumbel LM, Sang-ngoeng T et al.  
25 Antimicrobial efficacy of chlorhexidine and sodium hypochlorite in root canal  
26 disinfection: a systematic review and meta-analysis of randomized controlled  
27 trials. *J Endod* 2020;46:1032-1041 <http://doi.org/10.1016/j.joen.2020.05.002>
- 28 [7] Diogenes AR, Ruparel NB, Teixeira FB, Hargreaves KM. Translational science in  
29 disinfection for regenerative endodontics. *J Endod* 2014;40:S52-S57.  
30 <http://doi.org/10.1016/j.joen.2014.01.015>

- 1 [8] Rafter-M. Apexification: a review Dent Traumatol 2005;21:1-8. <http://doi:10.1111/j.1600-9657.2004.00284.x>
- 2
- 3 [9] Iglesias-Linares A, Yáñez-Vico RM, Sánchez-Borrego E, Moreno-Fernández AM, Solano-Reina E, Mendoza-Mendoza A. Stem cells in current paediatric dentistry practice. Arch Oral Biol 2013;58:227-238. <http://doi.org/10.1016/j.archoralbio.2012.11.008>
- 4
- 5
- 6
- 7 [10] Yang JY, Lee HS. Evaluation of antioxidant and antibacterial activities of morin isolated from mulberry fruits (*Morus alba L.*) J Korean Soc Appl Biol Chem 2012; 55:485–489. <http://doi.org/10.1007/s13765-012-2110-9>
- 8
- 9
- 10 [11] Wan J, Ma T, Jin Y, Qiu S (2020) The effects of morin on bone regeneration to accelerate healing in bone defects in mice. Int J Immunopathol Pharmacol 34:2058738420962909. <http://doi.org/10.1177/2058738420962909>
- 11
- 12
- 13 [12] Dias MC, Pinto DCGA, Silva MAS. Plant Flavonoids: Chemical Characteristics and biological activity. Molecules 2021; 26:5377. <https://doi.org/10.3390/molecules26175377>
- 14
- 15
- 16 [13] Gopal JV. Morin hydrate: botanical origin, pharmacological activity and its applications. Pharmacog J 2013;5:123–126. <https://doi.org/10.1016/j.phcgj.2013.04.006>
- 17
- 18
- 19 [14] Rajput SA, Wang XQ, Yan HC. Morin hydrate: A comprehensive review on novel natural dietary bioactive compound with versatile biological and pharmacological potential. Biomed Pharmacother 2021; 138:111511. <http://doi.org/10.1016/j.biopha.2021.111511>.
- 20
- 21
- 22
- 23 [15] Caselli A, Cirri P, Santi A, Paoli P. Morin: a promising natural drug Curr Med Chem 2016; 23: 774-791. <http://doi.org/10.2174/0929867323666160106150821>
- 24
- 25 [16] Sergediene E, Jönsson K, Szymusiak H, Tyrakowska B, Rietjens IMCM, Čenas N. Prooxidant toxicity of polyphenolic antioxidants to HL-60 cells: Description of quantitative structure-activity relationships FEBS Lett 1999:392–396. [http://doi.org/10.1016/s0014-5793\(99\)01561-6](http://doi.org/10.1016/s0014-5793(99)01561-6)
- 26
- 27
- 28
- 29 [17] Cho YM, Onodera H, Ueda M, Imai T, Hirose M A 13-week subchronic toxicity study of dietary administered morin in F344 rats. Food Chem Toxicol 2006;44:891–897. <http://doi.org/10.1016/j.fct.2005.12.002>
- 30
- 31

- 1 [18] Kopacz M, Woźnicka E, Gruszecka J. Antibacterial activity of morin and its  
2 complexes with La (III), Gd (III) and Lu (III) ions. *Acta Pol Pharm - Drug Res* 2005;  
3 62:65–67.
- 4 [19] Huang P, Hu P, Zhou SY, Li Q, Chen WM. Morin inhibits sortase A and  
5 subsequent biofilm formation in *Streptococcus mutans* *Curr Microbiol* 2014;  
6 68:47–52. <http://doi.org/10.1007/s00284-013-0439-x>
- 7 [20] Gutiérrez-Venegas G, Gómez-Mora JA, Meraz-Rodríguez MA, Flores-Sánchez  
8 MA, Ortiz-Miranda LF. Effect of flavonoids on antimicrobial activity of  
9 microorganisms present in dental plaque. *Heliyon* 2019; 5(12): e03013.  
10 <http://doi.org/10.1016/j.heliyon.2019.e03013>
- 11 [21] Abirami G, Alexpandi R, Durgadevi R, Kannappan A, Veera Ravi A. Inhibitory  
12 Effect of morin against *Candida albicans* pathogenicity and virulence factor  
13 production: an in vitro and in vivo approaches *Front Microbiol* 2020;23:11.  
14 <http://doi.org/10.3389/fmicb.2020.561298>
- 15 [22] Chemmugil P, Lakshmi PTV, Annamalai A. Exploring morin as an anti-quorum  
16 sensing agent (anti-QSA) against resistant strains of *Staphylococcus aureus*.  
17 *Microb Pathog* 2019; 127:304–315.  
18 <http://doi.org/10.1016/j.micpath.2018.12.007>
- 19 [23] de Farias AL, Meneguín AB, da Silva Barud H, Brighenti FL. The role of sodium  
20 alginate and gellan gum in the design of new drug delivery systems intended for  
21 antibiofilm activity of morin. *Int J Biol Macromol* 2020;162:1944–58.  
22 <http://doi.org/10.1016/j.ijbiomac.2020.08.078>
- 23 [24] Farias AL, Arbeláez MIA, Meneguín AB, Barud HDS, Brighenti FL. Mucoadhesive  
24 controlled-release formulations containing morin for the control of oral biofilms.  
25 *Biofouling* 2022;38:71-83. <http://doi.org/10.1080/08927014.2021.2015580>.
- 26 [25] Wang C, Wan X, Li Y, Zhang H, Zhang L. Morin protects glucocorticoid-induced  
27 osteoporosis through regulating the mitogen-activated protein kinase signaling  
28 pathway. *J Nat Med* 2018;72:929-936. [http://doi.org/10.1007/s11418-018-](http://doi.org/10.1007/s11418-018-1228-4)  
29 1228-4.
- 30 [26] Mu M, Li X, Tong A, Guo G. Multi-functional chitosan-based smart hydrogels  
31 mediated biomedical application. *Expert Opin Drug Deliv* 2019; 16:239-250.  
32 <http://doi.org/10.1080/17425247.2019.1580691>.

- 1 [27] Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407  
2 pharmaceutical and pharmacological characteristics Pharm Res 2006;23:2709-  
3 2728. <http://doi.org/10.1007/s11095-006-9104-4>
- 4 [28] Qu Y, Guan Z, Nan F, Liu S, Liu L. Effect and mechanism of ultraviolet-cross-  
5 linkable chitosan-carbon dots-morin hydrogel treating for rat cartilage injury.  
6 Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2022;36:1524-1533.  
7 <http://doi.org/10.7507/1002-1892.202208121>.
- 8 [29] Huang C, Peng L, Xu X, Lu Y, Wang X, Lan Z et al. Preparation and characteristics  
9 of a thermosensitive *in situ* gel loaded with chitosan nanoparticles for optimal  
10 ocular delivery of chloramphenicol. J Drug Deliv Sci Tech 2023;89:104962.  
11 <https://doi.org/10.1016/j.jddst.2023.104962>
- 12 [30] Dardouri M, Bettencourt A, Martin V, Carvalho FA, Santos C, Monge N et al.  
13 Using plasma-mediated covalent functionalization of rhamnolipids on  
14 polydimethylsiloxane towards the antimicrobial improvement of catheter  
15 surfaces. Biomater Adv 2022;134:112563.  
16 <http://doi.org/10.1016/j.msec.2021.112563>.
- 17 [31] IEEE Transactions on Systems, Man, and Cybernetics. Volume: 9, Issue: 1,  
18 January 1979. Available on the website:  
19 <https://ieeexplore.ieee.org/document/4310076> .
- 20 [32] Cunha C, Marinheiro D, Ferreira BJML, Oliveira H, Daniel-da-Silva AL. Morin  
21 hydrate encapsulation and release from mesoporous silica nanoparticles for  
22 melanoma therapy. Molecules. 2023;28:4776.  
23 <http://doi.org/10.3390/molecules28124776>.
- 24 [33] Singh P, Ansari Z, Ray S, Bandyopadhyay B, Sen K. Effect of  $\gamma$ -irradiation on  
25 ruthenium-morin nanocomposite for trace detection of Ce(IV), Ce(III) and Dy(III).  
26 Mat Chem Phys 2020;248:122949. [http://doi.org/](http://doi.org/10.1016/j.matchemphys.2020.122949)  
27 [10.1016/j.matchemphys.2020.122949](http://doi.org/10.1016/j.matchemphys.2020.122949).
- 28 [34] Dimitrić Marković JM, Marković ZS, Krstić JB, Milenković D, Lučić B, Amić D.  
29 Interpretation of the IR and Raman spectra of morin by density functional theory  
30 and comparative analysis. Vibrat Spectr 2013;64:1-9.  
31 [doi:https://doi.org/10.1016/j.vibspec.2012.10.006](https://doi.org/10.1016/j.vibspec.2012.10.006).

- 1 [35] Drabczyk A, Kudłacik-Kramarczyk S, Głąb M, Kędzierska M, Jaromin A,  
2 Mierzwiński D, Tyliszczak B. Physicochemical investigations of chitosan-based  
3 hydrogels containing *Aloe Vera* designed for biomedical use. *Materials (Basel)*  
4 2020;13:3073. <http://doi.org/10.3390/ma13143073>.
- 5 [36] Leyva-Gómez G, Santillan-Reyes E, Lima E, Madrid-Martínez A, Krötzsch E,  
6 Quintanar-Guerrero D et al. A novel hydrogel of poloxamer 407 and chitosan  
7 obtained by gamma irradiation exhibits physicochemical properties for wound  
8 management. *Mater Sci Eng C Mater Biol Appl.* 2017;.74:36-46.  
9 <http://doi.org/10.1016/j.msec.2016.12.127>.
- 10 [37] Vyas V, Sancheeti P, Karekar P, Shah M, Pore Y (2009) Physicochemical  
11 characterization of solid dispersion systems of tadalafil with poloxamer 407. *Acta*  
12 *Pharm* 59:453-461. <https://doi.org/10.2478/v10007-009-0037-4>.
- 13 [38] Garala K, Joshi P, Shah M, Ramkishan A, Patel J. Formulation and evaluation of  
14 periodontal in situ gel. *Int J Pharm Investig.* 2013;3:29-41.  
15 <https://doi.org/10.4103/2230-973X.108961>
- 16 [39] Aibani N, Rai R, Patel P, Cuddihy G, Wasan EK. Chitosan Nanoparticles at the  
17 Biological Interface: Implications for Drug Delivery. *Pharmaceutics*  
18 2021;13:1686. <http://doi.org/10.3390/pharmaceutics13101686>.
- 19 [40] Yazdanshenas R, Gharib F. Spectrophotometric determination of preferential  
20 solvation and solvation shell composition of morin hydrate in some water-  
21 aliphatic alcohol mixed solvents. *J Mol Liq* 2017;243:414-419.  
22 <https://doi.org/10.1016/j.molliq.2017.08.064>.
- 23 [41] Cruz MAE, Tovani CB, Favarin BZ, Soares MPR, Fukada SY, Ciancaglini P, Ramos  
24 AP. Synthesis of Sr-morin complex and its in vitro response: decrease in  
25 osteoclast differentiation while sustaining osteoblast mineralization ability. *J*  
26 *Mater Chem B* 2019;7:823-829. <http://doi.org/10.1039/c8tb02045k>
- 27 [42] Mondal S, Das S, Mahapatra PK, Saha KD. Morin encapsulated chitosan  
28 nanoparticles (MCNPs) ameliorate arsenic induced liver damage through  
29 improvement of the antioxidant system and prevention of apoptosis and  
30 inflammation in mice. *Nanoscale Adv* 2022;13:2857-2872.  
31 <http://doi.org/10.1039/d2na00167e>.

- 1 [43] Vimalraj S, Subramaniam R, Saravan S, Deepak T, Murugan K, Dhanasekaran  
2 A. Zinc chelated morin promotes osteoblast differentiation over its uncomplexed  
3 counterpart. Proc Biochem 2019;82: 167-172.  
4 <http://doi.org/10.1016/j.procbio.2019.04.008>
- 5 [44] Chen Y, Lee JH, Meng M, Cui N, Dai CY, Jia Q et al. An Overview on  
6 Thermosensitive Oral Gel Based on Ploxamer 407. Materials (Basel)  
7 2021;14:4522. <http://doi.org/10.3390/ma14164522>.
- 8 [45] Kant V, Gopal A, Kumar D, Gopalkrishnan A, Pathak NN, Kurade NP et al. Topical  
9 pluronic F-127 gel application enhances cutaneous wound healing in rats. Acta  
10 Histochem 2014;116:5-13. <http://doi.org/10.1016/j.acthis.2013.04.010>.
- 11 [46] Garbieri TF, Martin V, Santos CF, Gomes PS, Fernandes MH. The Embryonic  
12 Chick Femur Organotypic Model as a Tool to Analyze the Angiotensin II Axis on  
13 Bone Tissue. Pharmaceuticals (Basel) 2021;14:469.  
14 <http://doi.org/10.3390/ph14050469>.
- 15 [47] Araújo R, Martin V, Ferreira R, Fernandes MH, Gomes OS. A new ex vivo model  
16 of the bone tissue response to the hyperglycemic environment - The embryonic  
17 chicken femur organotypic culture in high glucose conditions. Bone  
18 2022;158:116355. <http://doi.org/10.1016/j.bone.2022.116355>.
- 19

1 **List of Figure legends:**

2 **Figure 1.** Characterization of morin (M) and the synthesized particles. Morin' chemical structure  
3 (a), morphology (b) and chemical composition (c), assessed through SEM and EDS. Light (d, g) and  
4 SEM representative images from the surface of CP (e, f), and MCP (h, i) hydrogel particles. (n=3).

5 **Figure 2.** Cumulative released morin from the loaded chitosan-poloxamer (MCP) particles  
6 assessed by colorimetric evaluation. (n=3, SD 1.7 – 5.6%).

7 **Figure 3.** In vitro biological characterization of morin. Normalized metabolic activity (a),  
8 quantitative ALP activity (b) and representative fluorescent images of cell morphology (lower  
9 panel) of HBMSCs cultivated in osteogenic medium and morin for 7 days. Control (Morin at 0  
10  $\mu\text{g/mL}$ ) is set at 100%. Stained F-actin is displayed in green, while nuclei were counter-stained  
11 in blue. Scale bar corresponds to 100  $\mu\text{m}$ . \* Statistically different from control. # Statistically  
12 different from other experimental groups.  $p < 0.05$ . Metabolic and ALP activities, n=5. Cell  
13 morphology, n=3. SD 3.2 to 6.6%.

14 **Figure 4.** Normalized metabolic activity of HBMSCs cultivated with leachates of chitosan-  
15 poloxamer hydrogels (CP and MCP) for 24 h (a) and 7 days (b). X axis values represent the  
16 timepoints of leachates' collection. Control (absence of leachates of the referred timepoint) is  
17 set as 100%. \* Statistically different from control.  $p < 0.05$ , n=5. SD 5.4 to 19.7%.

18 **Figure 5.** Normalized metabolic and ALP activity (upper panel) and representative fluorescent  
19 images (lower panel) of HBMSCs cultivated indirectly with chitosan-poloxamer gels (blank and  
20 containing morin) in osteogenic medium for 7 days. Control (C, absence of particles) is set as  
21 100%. F-actin is stained in green, and nuclei were counter-stained in blue. Scale bar is set as 100  
22  $\mu\text{m}$ . \* Statistically different from control.  $p < 0.05$ . Metabolic and ALP activities, n=5, Cell  
23 morphology, n=3. SD 9.5 – 13.9%.

24 **Figure 6.** Representative images of histological sections of the organotypic bone model. Femora  
25 were fractured and involved with chitosan-poloxamer gels (blank and containing morin).  
26 Samples were incubated for 11 days. (a) Femora sections were stained with Alcian Blue with  
27 Sirius Red AB/SR (particles were stained in red), and (b) Von Kossa. Scale bar was set as 1 mm.  
28 (c) Quantitative analysis of collagen deposition and mineralized area. Control (absence of  
29 particles) is set as 100%. \*Statistically different from control. # Statistically different from other  
30 experimental samples. \*  $p < 0.05$ , n=3. SD 8.8 – 12.4%.

31